2025年体外诊断业务展望（6期）

In Vitro Diagnostics Business Outlook, 2025 (6 Issues)

出版日期: 2025年01月24日 | 出版商:

Kalorama Information | 英文 | 商品交期: 最快1-2个工作天内

价格

简介目录

体外诊断（IVD）领域是现代医疗保健的基石，为临床医生提供检测疾病、监测健康状况和做出有针对性的治疗决策的工具。

范例

随着医疗保健的发展，IVD市场可望实现转型成长。随着糖尿病和心血管疾病等慢性病的发病率上升，以及新冠肺炎等传染病及其变种的持续威胁，对创新诊断解决方案的需求从未如此高涨。

本报告每两个月出版一次，每年出版六次，每期重点关注 IVD 行业的不同领域，并提供市场资料和预测、全面的市场前景、併购活动、垂直和区域趋势。

公告
- Roche质谱系统获得 CE 标誌
- QIAGEN 的五种针对性综合征检测试剂盒获得 FDA 批准
- Revvity 已获得 FDA 批准提供免费睾酮测试
- Spear Bio 获得 FDA 突破性设备认证
- Roche宣布批准首个 B 细胞淋巴瘤 ISH 检测
- Roche获得 FDA 的额外批准

简介目录

Product Code: 25-014KA

The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.

SAMPLE VIEW

As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.

"In Vitro Diagnostics Business Outlook" is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:

Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
Comprehensive Market View: Coverage of test categories and company profiles.
M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.

MARKET ANALYSIS: CARDIAC BIOMARKER TESTING

OVERVIEW OF CARDIAC BIOMARKERS

MARKET OUTLOOK

Figure: Cardiac Marker Testing Market by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Table: Cardiac Marker Diagnostic Sales by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Figure: Cardiac Marker Testing Market by End User and Total Value Over Time, 2019-2029 ($ million) (Lab-based, PoC-based)
Figure: Cardiac Marker Testing Market, by Marker, 2024 (% Share) (Troponin, BNP, CK-MB, Myoglobin, Other)
REGIONAL MARKET
- Table: Cardiac Marker Test Sales Distribution by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
COMPANY BRIEFS
- Abbott Diagnostics
- Beckman Coulter
- Siemens
VENDOR MARKET SHARE
- Figure: Market Share of Leading Vendors in the Cardiac Marker Segment, by Company, 2024 (%) (Abbott, Danaher, QuidelOrtho, Roche, Siemens, Others)

EXECUTIVE NEWS BRIEFING

BRIEFS
- Senseera Closes $7.1 Million in Funding Round
- Geneoscopy Closes Series C Funding
- Oxford Cancer Analytics Raises $11 Million in Series A Funding
- MiRXES Nabs $40 Million in Financing
- Tethis Nabs Euro-15 Million Funding

FINANCIAL HIGHLIGHTS: BECTON DICKINSON, NATERA

BECTON DICKINSON REPORTS 4% REVENUE GROWTH IN FISCAL 2024
- Table: Becton Dickinson Financial Review, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
- Figure: Becton Dickinson Business Division Performance, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
- Figure: BD Life Sciences Division, Segment Mix, FY 2020 vs. FY 2024 (%) (Integrated Diagnostic Solutions, Biosciences)
- Figure: Becton Dickinson U.S./International Revenue Distribution, FY 2022-FY 2024 ($ million)
- Figure: Becton Dickinson Revenue Distribution, by Region, FY 2024 (%) (EMEA, Greater Asia, United States, Other)
NATERA CONTINUES OVERALL GROWTH TREND WITH PRELIMINARY 2024 RESULTS, EXPECTING A 56% INCREASE OVER 2023
- Figure: Natera Financial Overview by Quarter, Q1 2023-Q4 2024* ($ million)

DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS

PARTNERSHIPS AND COLLABORATIONS
MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, Dec. 2023-Jan. 2025

INDUSTRY WATCH

INDUSTRY WATCH COVID-19/FLU UPDATE

REGION WATCH

MEXICO
- Figure: Mexico GDP, GDP (PPP), and Health Spending, 1990-2020, estimated 2025 ($ billion)
- Figure: Mexico IVD Market Sales Trends, by Broad IVD Segment, 2016-2024 ($ million) (Clinical Chemistry, Hematology, and Coagulation; Histology; Immunoassays; Microbiology; POC; Others)

BROAD-BASED COMPANY ANNOUNCEMENTS

ANNOUNCEMENTS
- Roche Secures CE Marking for Mass Spec System
- QIAGEN Receives FDA Clearance for Five-Target Syndromic Panel
- Revvity Secures FDA Clearance for Free Testosterone Test
- Spear Bio Secures FDA Breakthrough Device Designation
- Roche Announces Clearance of First ISH Test B-cell Lymphoma
- Roche Receives Additional FDA Clearance

02-2729-4219

+886-2-2729-4219